Thoma Bravo is exploring a potential $7bn sale of healthcare identity software provider Imprivata. This move comes as the private equity firm seeks to cash in on its investment, highlighting the growing interest in healthcare technology.

The sale of Imprivata could be a significant exit for Thoma Bravo, which acquired the company in 2016. Imprivata's strong performance in the healthcare sector, particularly in identity and access management, has made it an attractive asset. The potential $7bn valuation underscores the value created under Thoma Bravo's stewardship and the firm's strategic investments in the sector.

This development comes amid a wave of private equity exits in the technology sector, with healthcare tech standing out as a particularly hot area. Investors are watching closely to see how this deal unfolds, as it may set a precedent for future exits in the sector. The sale process is expected to draw significant interest from potential buyers, including other private equity firms and strategic acquirers looking to expand their healthcare technology offerings.

Private Equity Insights reports that the sale process is already underway, with several potential buyers expressing interest. The outcome of this deal will not only affect Thoma Bravo's portfolio but also influence the broader healthcare technology market, which has seen a surge in activity in recent years. As the sector continues to evolve, such high-value exits are likely to become more common.